Publications (2)0 Total impact
-
Article: Coronary angiographic profile in bangladeshi patients with metabolic syndrome and ischemic heart disease.
[show abstract] [hide abstract]
ABSTRACT: The metabolic syndrome, which is characterized by a constellation of fasting hyperglycemia, hypertriglyceridemia, low HDL cholesterol, hypertension, and/or abdominal obesity, is a risk factor for the development of coronary artery disease (CAD) and cardiovascular events. We evaluated interrelationships between angiographic CAD and the metabolic syndrome, in 478 patients who were referred for coronary angiography to evaluate suspected myocardial ischemia in the department of cardiology of BSMMU between June 2007 and May 2008. We applied the criteria for the metabolic syndrome proposed by ATP III guideline. Study populations were divided into two groups on the basis of presence or absence of metabolic syndrome. Age was similar in both groups. Body mass index (BMI) was higher (26.22±1.94 vs. 22.07±1.55) in metabolic syndrome group (p≤0.0001). All parameters, waist circumference (103.16±10.21 vs. 91.45±7.61) cm, blood pressure both systolic (141.34±21.49 vs. 127.94±13.01) and diastolic (86.85±8.42 vs. 79.28±7.77) mm of Hg, serum triglyceride (248.32±77.88 vs. 128.35±19.00)mg/dl, fasting blood glucose (125.40±22.86 vs. 95.65±10.63)mg/dl were significantly higher in metabolic syndrome group (p value=0.0001), whereas HDL (33.10±6.55 vs. 39.30±6.17)mg/dl was lower (p value = 0.0001). More subjects in metabolic syndrome were having type B (55.60% vs. 31.00%) and type C (9.50% vs. 2.70%) lesion as compared to non-metabolic syndrome group. Involvement of left main artery was more (4.80% vs. 0.90%) in metabolic syndrome group. Metabolic syndrome has primary predictive ability for CAD. A metabolic profile should form part of the risk assessment in all patients with coronary disease, not just those who are obese.Mymensingh Medical Journal 10/2012; 21(4):702-8. -
Article: Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram.
[show abstract] [hide abstract]
ABSTRACT: This prospective randomized, controlled trial was done to evaluate the efficacy of trimetazidine in the prevention of contrast induced nephropathy in patients with raised serum creatinine levels undergoing coronary angiogram. This study was performed in the Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from April 2009 to March 2010. Contrast-induced nephropathy (CIN) is a serious complication of coronary angiography that is associated with considerably increased mortality and morbidity, including the need for short-term haemodialysis, extended hospitalisation and permanent impairment of renal function. Trimetazidine (TMZ) has been described as a cellular anti-ischaemic agent. This study was trial with 400 patients. Among them 200 patients treated with trimetazidine plus hydration with normal saline and 200 patients (control) given hydration by normal saline only. It was found that the incidence of CIN was significantly (p<0.05) reduced by trimetazidine administration with saline in comparison with saline alone in patients undergoing coronary angiogram (4% vs. 14%).Mymensingh Medical Journal 04/2012; 21(2):292-9.
